Ocata Therapeutics Inc  

(Public, NASDAQ:OCAT)   Watch this stock  
Find more results for OTC:ACTC
4.49
+0.24 (5.65%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.23 - 4.87
52 week 3.55 - 12.73
Open 4.35
Vol / Avg. 977,764.00/565,816.00
Mkt cap 188.40M
P/E     -
Div/yield     -
EPS -1.05
Shares 35.67M
Beta 1.21
Inst. own 4%
Aug 6, 2015
Q2 2015 Ocata Therapeutics Inc Earnings Call - 4:30PM EDT - Add to calendar
Jul 8, 2015
Ocata Therapeutics Inc at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 1, 2015
Ocata Therapeutics Inc at Jefferies Global Healthcare Conference
May 7, 2015
Q1 2015 Ocata Therapeutics Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -17825.11% -22009.72%
Operating margin -17840.31% -22249.30%
EBITD margin - -13499.45%
Return on average assets -531.69% -720.53%
Return on average equity - -
Employees 37 -
CDP Score - -

Address

33 Locke Dr
MARLBOROUGH, MA 01752-1167
United States - Map
+1-508-7561212 (Phone)
+1-508-2292333 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Officers and directors

Michael Thomas Heffernan Independent Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Paul K. Wotton Ph.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Edward Myles CPA Chief Financial Officer, Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
LeRoux Jooste Senior Vice President - Business Development, Chief Commercial Officer
Age: 59
Bio & Compensation  - Reuters
Robert P. Lanza M.D. Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
John Heffernan Vice President - Manufacturing
Bio & Compensation  - Reuters
Eddy Anglade M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Robert S. Langer Independent Director
Age: 66
Bio & Compensation  - Reuters
Zohar Loshitzer Independent Director
Age: 57
Bio & Compensation  - Reuters
Gregory D. Perry Independent Director
Age: 54
Bio & Compensation  - Reuters